Bristol Myers Squibb Company (BMY) To Go Ex-Dividend on July 2nd

Bristol Myers Squibb Company (NYSE:BMY) declared a quarterly dividend on Wednesday, June 17th. Stockholders of record on Thursday, July 2nd will be given a dividend of 0.63 per share by the biopharmaceutical company on Monday, August 3rd. This represents a c) annualized dividend and a dividend yield of 4.7%. The ex-dividend date is Thursday, July 2nd.

Bristol Myers Squibb has increased its dividend payment by an average of 0.0%annually over the last three years and has increased its dividend annually for the last 17 consecutive years. Bristol Myers Squibb has a payout ratio of 41.5% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Bristol Myers Squibb to earn $6.05 per share next year, which means the company should continue to be able to cover its $2.52 annual dividend with an expected future payout ratio of 41.7%.

Bristol Myers Squibb Price Performance

BMY opened at $54.10 on Friday. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42. The stock has a market capitalization of $110.48 billion, a PE ratio of 15.20, a price-to-earnings-growth ratio of 0.16 and a beta of 0.24. The stock’s 50 day moving average price is $57.44 and its 200-day moving average price is $57.11. Bristol Myers Squibb has a 52-week low of $42.52 and a 52-week high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $1.42 by $0.16. The business had revenue of $11.49 billion for the quarter, compared to analysts’ expectations of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The firm’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.80 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, equities research analysts predict that Bristol Myers Squibb will post 6.32 EPS for the current year.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.